| Name | Title | Contact Details |
|---|
Nobu, the world-renowned Japanese restaurant recognized for pioneering a new-style Japanese cuisine, started as a business partnership in 1994 between Chef Nobu Matsuhisa and his partners, Academy Award-winning actor Robert De Niro, producer Meir Teper, and restaurateur Drew Nieporent. Originating in New York as the flagship restaurant, the Nobu brand is now an empire that spans five continents with over 40 restaurants and growing. Following the success of the restaurants, Nobu Hospitality opened the first Nobu Hotel in 2013 in Las Vegas and today has 13 hotels open with several more in development.
For more than a quarter of a century, Specialty Lighting Group has provided quality lighting products and design services for a variety of national clients. We create lasting value by offering a big companys expertise and resources with a small companys attention to service and detail. Be it a retail location or restaurant, we generate computerized lighting layouts and assist your designer or architect to ensure the lighting is appropriate for the application, energy-efficient, and available to meet your schedule. We also provide energy audits to assess the efficiency of your current lighting setup and figure out what utility rebates your company may be entitled to. Additionally, we provide a plan to increase the efficiency of your lighting and attempt to garner the greatest amount of utility rebates possible to save not only energy, but your money as well. With our large list of lighting and lamp vendors, we guarantee that we can provide you the perfect fixture or lamp for your project and our large inventory ensures that your lighting will arrive on time, no matter how tight your schedule may be. To find out more about Specialty Lighting Group, visit our website at www.sslighting.com, or watch the following video: http://sslighting.com/Images/specialty_lighting_wb.swf
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
With a legacy of achievement and innovation, R.H. Sheppard Cp., Inc. is a global leader in power steering and diesel engine pump technologies for the commercial vehicle industry, with the introduction of the D-Series family of power steering gears and the continued development of the M-Series. Today Sheppard continues to develop and introduce new steering system products, including miter and T-boxes, miter columns, steering columns, and other linkages. Sheppards headquarters campus is in Hanover, Pa., where it conducts engineering, testing, manufacturing, remanufacturing, and distribution. It also operates a machining facility in Wytheville, Va., along with an R&D Center in Shelby Township, Mich.